Languages  By theme  By sector  By country
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
SANOFI-AVENTIS [FR0000120578/SAN]   
[06/01/2014]

SANOFI-AVENTIS : Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Reg

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofi a French société anonyme with a... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[12/12/2013]

SANOFI-AVENTIS : Merial Receives EMA approval for Broadline™ for Broad Spectrum Parasite Treatment and Prevention in Cats

PRESS RELEASE Merial Receives EMA approval for Broadline(TM) for Broad Spectrum Parasite Treatment and Prevention in Cats - New Product is a Broad Spectrum Topical Feline Endectocide from Sanofi's Animal Health Division, Adds to Company's Strong Parasiticide Portfolio - Paris, France - December 12, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[11/12/2013]

SANOFI-AVENTIS : FDA Grants Priority Review for Genzyme’s Cerdelga™ (eliglustat), an Investigational Oral Therapy for Gaucher Disease

PRESS RELEASE FDA Grants Priority Review for Genzyme's Cerdelga(TM) (eliglustat), an Investigational Oral Therapy for Gaucher Disease - Second Major Regulatory Filing Following EMA Acceptance in Late October - Paris, France - December 11, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the Food and Drug Administration... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[05/12/2013]

SANOFI-AVENTIS : New Data Support Flexibility in Timing of Administration for Sanofi’s Lyxumia®

PRESS RELEASE Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial - Sarilumab, Given Subcutaneously Every Other Week, Met All Three Co-Primary Endpoints - - Sarilumab is the First Fully-Human Monoclonal Antibody Directed Against the ... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[03/12/2013]

SANOFI-AVENTIS : Sanofi Announces New Phase 3 Results for Investigational New Insulin U300

PRESS RELEASE Sanofi Announces New Phase 3 Results for Investigational New Insulin U300 - EDITION II trial demonstrates similar blood sugar control with fewer night-time low blood sugar events for U300 compared with Lantus(r) - - EDITION III, IV and JP I studies meet primary endpoint - Paris, France - December 3, 2013 - Sanofi announced the full results... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[26/11/2013]

SANOFI-AVENTIS : Information concerning the total number of voting rights and shares

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofi a French société anonyme with a registered share... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[22/11/2013]

SANOFI-AVENTIS : Sanofi Pasteur commends GAVI Alliance for Supporting the Introduction of Inactivated Polio Vaccine in World’s Poorest Countries

PRESS RELEASE Sanofi Pasteur commends GAVI Alliance for Supporting the Introduction of Inactivated Polio Vaccine in World's Poorest Countries - Sanofi Vaccines division well positioned to contribute to further expansion of Alliance portfolio - Lyon, France - November 22, 2013 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN... See more
 
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
Videos
Gestionnaires,
Emetteurs,
My favourite companies
Most read news of SANOFI-AVENTIS
Dissemination technology Webdisclosure.com - copyright 2019 SYMEX ECONOMICS all rights reserved